A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Biotech company Regeneron (NASDAQ:REGN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 19% year on year to $3.61 billion...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 7.1% in the afternoon session after its first-quarter 2026 earnings report revealed sig...
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 19% year on year to $3.61 billion. I...
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Wednesday morning. Here’s what to expect. Regeneron beat analysts’ revenue expectatio...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]
Over the past six months, Regeneron has been a great trade, beating the S&P 500 by 32.3%. Its stock price has climbed to $767, representing a healthy 35.8% i...
The United States labor market is currently defying traditional economic gravity, showcasing a resilient "low-hire, low-fire" dynamic that has left analysts and investors recalibrating their expectations for the remainder of the year. Recent data for the week ending March 28, 2026, shows initial jobless claims fell by 9,000 to
By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific purity and internal innovation. For decades, the Tarrytown-based firm avoided the large-scale, "growth-by-acquisition" strategies of its peers, choosing instead to bet on the proprietary genetic research of [...]
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
